The article presents results of the BRIO-I study, a clinical trial of Brimochol PF, a topical fixed-dose combination for the treatment of presbyopia from Visus Therapeutics, which references a research paper by R. S. Verhoeven et al., published in a 2022 issue of the "Investigative Ophthalmology & Visual Science." It discusses a comparison of a single dose of the drug with individual monotherapies, and the implications of the study for future medical presbyopia correction.
The article elaborates on the research commissioned by the College of Optometrists regarding the implication of most behavioural optometry techniques in Great Britain. Researchers found that the findings correspond with the previously published paper done by Dr. Adrian Jennings in 2000, stressing that there was a lack of controlled clinical trials to support behavioural management strategies.
Published
2008
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.